Danish pharmaceutical company ALK managed to do better than predicted in the first three months of the year measured by income as well as revenue.
The firm, which produces allergy medications, had a DKK 1.021bn (USD 165.0m) revenue in January, February and March put together, up against DKK 956m in the same period last year. Analysts had predicted sales amounting to DKK 1bn, according to estimates collected by ALK.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.